Email updates

Keep up to date with the latest news and content from Malaria Journal and BioMed Central.

Open Access Commentary

CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives

Ian C Boulton1, Solomon Nwaka2, Ian Bathurst3, Michael Lanzer4, Donatella Taramelli5, Henri Vial6, Christian Doerig7, Kelly Chibale8 and Steve A Ward9*

Author Affiliations

1 TropMedPharma Consulting Ltd, 10 Brampton Chase, Lower Shiplake, Oxfordshire RG9 3BX, UK

2 Special Programme for Research & Training in Tropical Diseases (TDR), World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland

3 Medicines for Malaria Venture, PO Box 1826, ICC Building, 20, rte de Pré-Bois, 1215 Geneva 15, Switzerland

4 Department of Parasitology, University of Heidelberg, 69120 Heidelberg, Germany

5 Department of Sanità Pubblica-Microbiologia-Virologia, Università di Milano, Via Pascal 36, 20133 Milano, Italy

6 Centre National de la Recherche Scientifique, UMR 5235, Université Montpellier 2, Place Eugene Bataillon, 34095 Montpellier Cedex 5, France

7 Inserm-EPFL Joint Laboratory, Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland

8 Department of Chemistry, University of Cape Town, Rondebosch, Cape Town, 7701, South Africa

9 Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK

For all author emails, please log on.

Malaria Journal 2010, 9:202  doi:10.1186/1475-2875-9-202

Published: 13 July 2010

Abstract

Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented. The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted.

The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade.